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INPATIENT BURDEN OF ILLNESS AND PREDICTORS OF CHARGES OR 
LENGTHS OF STAY AMONG ADULT HEART TRANSPLANTATION
PATIENTS
Olvey EL, Skrepnek GH
University of Arizona, Tucson, AZ, USA
OBJECTIVES: To assess the role of hospital, patient, payer and clinical factors 
on inpatient hospital lengths of stay (LOS) and total charges in adults undergoing 
heart transplantation. METHODS: This analysis utilized the nationally representative 
inpatient hospital discharge records from the Agency for Healthcare Research and
Quality (AHRQ) Healthcare Cost and Utilization Project (H-CUP) Nationwide
Inpatient Sample (NIS) from 2002 to 2005. All patients above 18 years of age
receiving a heart transplantation procedure were selected for inclusion. Speciﬁ c vari-
ables of interest included patient demographics (e.g., age, sex, race, income), hospital
characteristics (e.g., rural/urban), payer (e.g., Medicare, commercial, uninsured), 
procedures, diagnoses, case-mix risk adjustment (e.g., all patient reﬁ ned DRG (APR-
DRG)), and inpatient mortality. Outcomes analyzed were LOS and total charges. 
Gamma and negative binomial generalized linear models with log-links were employed 
with an a priori alpha of 0.05 for statistical signiﬁ cance. Human subjects approval 
was obtained from the University of Arizona. RESULTS: Overall, 5911 patients
underwent a heart transplantation between 2002–2005, with 74.1% of these patients
being males. Mean charges were $332,617 o $212,403. Average LOS was 41.76 o
50.16 days. Inpatient mortality was 5.4%. Regression analyses indicated signiﬁ cant 
associations between charges and number of procedures (Incidence Rate Ratio (IRR) 
 1.074, 95% CI  1.059–1.089), inpatient mortality (IRR  1.274, 95% CI 
1.094–1.483), APR-DRG (IRR  1.126, 95% CI  1.061–1.195), African-American 
race (IRR  0.871, 95% CI  0.783–0.969), and hospital location (IRR small metro-
politan  0.799, 95% CI  0.731–0.874, IRR micropolitan/rural  0.741, 95% 
CI  0.661–0.831). These analyses also indicated signiﬁ cant associations between LOS 
and number of diagnoses (IRR  0.979, 95% CI  0.960–0.997), number of proce-
dures (IRR  1.104, 95% CI  1.082–1.126), APR-DRG (IRR  1.291, 95% CI 
1.136–1.467), and hospital location (IRR micropolitan/rural  0.779, 95% CI 
0.635–0.958). CONCLUSIONS: This investigation of 5911 adult heart transplant 
patients suggests that several factors are signiﬁ cantly associated with LOS and charges. 
Continued research, particularly subgroup analyses and long term follow-up, are
warranted.
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ECONOMIC BURDEN OF ATHEROSCLEROSIS AMONG PATIENTS WITH
TYPE-2 DIABETES MELLITUS
Ohsfeldt RL1, Gandhi SK2, Fox KM3, Bullano M2
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OBJECTIVES: The present study estimated cardiovascular event rates and direct
medical costs attributable to the medical management of type-2 diabetes mellitus 
(T2DM) patients with diagnosed atherosclerosis. METHODS: Using national admin-
istrative claims data, the number of cardiovascular (CV) events (i.e., myocardial 
infarction, stroke, revascularization) and direct costs of care were quantiﬁ ed among
patients 17 years of age with T2DM and, with or without an ICD-9 diagnostic 
code for coronary or cerebral atherosclerosis between January 1, 2002 and December
31, 2004. Patients with a CV event in the 12 months prior to index date were excluded. 
A comparison cohort (n  14,188) with T2DM and no atherosclerosis diagnosis
was matched on age, gender, geography, and Charlson comorbidity score to patients 
with diagnosed atherosclerosis and T2DM (n  10,842). Differences between patient 
groups were tested for CV event rates per 1000 patients and monthly costs for 
12 months pre- and post-diagnosis. RESULTS: The cohorts included 55% men 
with a mean age of 60.5 years (30% were   65 years of age). Patients with 
atherosclerosis and T2DM had 239 CV events/1000 patients and the comparison 
cohort with T2DM had 39.8/1000 patients at 12 months post-index date, p  0.01. 
Mean total cost of care for patients with atherosclerosis and T2DM was $10,039 
for the 12 months before and $18,371 for 12 months post-diagnosis, an 83% 
increase. One-year post-index total costs were signiﬁ cantly higher among atheroscle-
rosis and T2DM patients than the comparison cohort ($18,371 vs. $5,765, p  0.01). 
The attributable cost (difference between atherosclerosis pre- and post costs and 
comparison pre- and post costs) for atherosclerosis was $627 per month ($7524 
for 1 year). CONCLUSIONS: Patients with diagnosed atherosclerosis and T2DM
have substantial medical and economic burden attributable to their atherosclerosis. 
Utilizing administrative data, health plans may identify these patients for more effec-
tive management and treatment of their underlying atherosclerosis to reduce this
burden.
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MANAGEMENT OF PRIMARY ATRIAL FIBRILLATION (AF): 
PATIENT CHARACTERISTICS AND HOSPITAL CARE SETTING
Spalding JR1, Exuzides A2, Colby C2, Neil N2, Noe L2
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OBJECTIVES: To describe and differentiate characteristics and costs of patients 
admitted for treatment of primary AF in hospital emergency department (ED) and
inpatient settings. METHODS: Analysis of 2004–2005 discharges from the Premier 
Perspective database, including patients with primary AF diagnoses and evidence of 
initial therapy with electric conversion (EC) or an IV antiarrhythmic (amiodarone,
ibutilide or procainamide). RESULTS: Of 11108 discharges evaluated, 34% were 
admitted directly as inpatients and 66% presented to the ED. Of these, 14% were 
treated and released from the ED; the remaining 86% were transferred to the inpatient 
setting. ED patients were signiﬁ cantly (p  0.0001) younger with fewer comorbidities 
(p  0.0001) than either transfer or direct admit patients. Initial conversion therapy 
for the vast majority (79%) of ED treated patients was either EC or ibutilide, both of 
which are fast acting. Only 10% of ED patients received initial amiodarone. In con-
trast, 52% (42%) of transfer (direct) patients were treated with initial amiodarone 
and 39% (54%) received initial EC or ibutilide. About 4% of ED patients required a 
second conversion attempt compared to 13% of inpatient discharges. Median LOS 
was 4 days for both direct admit and transfer patients. Average costs were highest
among direct admit ($9229) vs. transfer ($8811) and ED ($1209) patients (p 
0.0001). CONCLUSIONS: Health care resource utilization is high for patients pre-
senting with acute AF and varies signiﬁ cantly by hospital care setting. Adjusted 
average costs of treating primary AF in the inpatient setting are signiﬁ cantly higher 
than the costs of treatment in the ED. Patient characteristics and selected method of 
cardioversion may impact both choice of care setting and costs. In clinically appropri-
ate patients, the availability of fast-acting conversion therapies suitable for use in the 
ED may obviate the need for inpatient admission and, thus, reduce the health care
burden of treating AF in the US.
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INPATIENT RESOURCE USE AMONG PATIENTS TREATED FOR PRIMARY
ATRIAL FIBRILLATION (AF): ROLE OF CLINICAL FACTORS AND CHOICE
OF INITIAL CONVERSION THERAPY
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OBJECTIVES: Prior analyses showed that AF patients treated with initial IV
amiodarone had signiﬁ cantly higher adjusted average resource use compared 
with other therapies. This analysis assesses whether these results can be explained 
by presence of classic AF covariate (AFC) diagnoses (heart failure; peripheral vascular
disease). METHODS: We used 2004–05 discharges from the Premier Perspective
database, including patients with primary AF diagnoses and evidence of initial 
therapy with electric conversion (EC) or an IV antiarrhythmic [amiodarone (AM), 
ibutilide (IB) or procainamide (PR)]. Patients were classiﬁ ed by AFC status. Inpatient 
costs and LOS were adjusted for clinical, demographic and hospital factors. RESULTS:
We stratiﬁ ed 10048 discharges into groups with AFC (28%) and without. Results 
showed that patients with AFC had higher costs (p  .0001) and longer LOS overall 
(p  .0001) and were 34% more likely to be treated with initial AM (p  .0001) vs. 
patients without, thus explaining some of the differences observed earlier. However,
resource use with initial AM remained signiﬁ cantly higher than with any other 
initial therapy regardless of patients’ AFC status. Among those without AFC,
adjusted average costs were $440$1988 higher (p  .0001) and LOS was 0.4–1 
day longer (p  .0001) with initial AM than with any other initial therapy. Among
patients with AFC, initial AM was $1602–$3266 higher (p  .0001) and LOS 
was 1.1–1.5 days longer (p  .005) than with any other initial therapy. CONCLU-
SIONS: There are signiﬁ cant inpatient cost and LOS differences among AF patients
depending on initial therapy and presence of AFC. Patients with AFC had higher 
adjusted average costs and LOS than those without and were more likely to be treated
with initial AM. However, adjusted average costs and LOS were highest among 
patients treated with initial AM regardless of AFC status. Further research should 
explore whether factors such as time to conversion affect resource use among these
patients.
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ADMINISTRATIVE DATABASES
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OBJECTIVES: To estimate the economic burden of AMI incident events registered 
in 2003 in Lombardy, the most inhabited region of Italy. METHODS: Data were 
extracted from health care administrative databases of Lombardy Region, which 
covers a population of about 9.2 million members. Administrative Healthcare 
databases related to eligibility criteria, hospital admissions (HA), pharmaceutical 
and outpatient claims of Lombardy Region citizens have been organized, using pro-
babilistic record linkage, in a data warehouse, called DENALI, to facilitate processing
and analysis. Using DENALI, we conducted a longitudinal and naturalistic study
on the burden of incident AMI in the perspective of the regional health service
(RHS). We identiﬁ ed all individuals with a HA for incident AMI (ICD-9-CM 
codes 410.xx, excluding codes 410.x2) during the year 2003 and followed them up 
to dec.31st 2005, death or transfer. We used charges to the RHS to quantify the 
economic burden of AMI to the RHS. Outcomes were quantiﬁ ed in term of morbidity
(sequelae) and mortality. We report on cost (overall and monthly cost-per-patient) and 
mortality. RESULTS: During 2003, 12,049 individuals (64% males, mean age 70
/13 y.o.) had a HA for incident AMI. A total of 3380 (28%) subjects died during 
an average follow-up period of 23 months. The total cost for all patients during the
ﬁ rst year was €163 million, corresponding to the 1% of the health care budget of 
